6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , R 1 , and Q 1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
1. A process for preparing a compound of Formula I comprising reacting a compound of formula I-AAA with Q 1 -B(OR) 2 under suitable coupling conditions according to the following scheme:
wherein A 11 is Br or I;
B(OR) 2 is a boronic acid or ester;
Q 1 is
E 11a is H or CH 3 ; E 11b is H or F;
R 1 is
and
G 11a and G 11b are each independently H, —CH 3 , —OH, —CH 2 OH,
2. The process of claim 1 , wherein R 1 is
3. The process of claim 2 , wherein E 11a and E 11b are both H.
4. The process of claim 3 , wherein A 11 is Br.
5. The process of claim 1 , wherein the compound of formula I-AAA is prepared by treating a compound of formula II-Z with ammonia
6. The process of claim 5 , wherein A 11 is Br.
7. The process of claim 6 , wherein R 1 is:
8. The process of claim 7 , wherein E 11a and E 11b are both H.